KRAS and colorectal cancer: Table 2 summarizes ongoing clinical trials evaluating KRAS G12C inhibition in patients with KRAS G12C-mutated colorectal cancer, and Table 3 summarizes the most relevant differences between adagrasib, sotorsaib, and divarsib.